Overexpression of ErbB2 and ErbB3 is found in several human cancers, and ErbB2-ErbB3 heterodimers are known as the most potent signaling units among ErbB dimers. While ErbB2 probably undergoes weak endocytosis, ErbB3 is readily internalized even in the absence of added ligand and without requirement for kinase activity. Overexpression of ErbB2 has been demonstrated to inhibit epidermal growth factor-induced internalization and degradation of epidermal growth factor receptor. This happens due to epidermal growth factor receptor-ErbB2 dimerization and can be counteracted by the anti-ErbB2 antibody pertuzumab, which binds the dimerization arm of ErbB2. Pertuzumab does also inhibit ErbB2-ErbB3 dimerization, but to what extent this has effect on constitutive and/or ligand-induced downregulation of ErbB3 is not known. In this study, we demonstrate that expression of ErbB2 as such did not block constitutive internalization of ErbB3, but that heregulin-induced degradation of ErbB3 was significantly slowed in cells expressing high levels of ErbB2. Incubation with pertuzumab did, however, counteract this effect. This indicates that the formation of ErbB2-ErbB3 heterodimers inhibits downregulation of ErbB3 and supports the notion that pertuzumab inhibits ErbB2 dimerization. The inhibitory effect of pertuzumab on ligandinduced ErbB2-ErbB3 heterodimerization was confirmed by the observation that pertuzumab inhibited heregulin-induced phosphorylation of ErbB3 in cells expressing ErbB2 and efficiently reduced heregulin-induced downstream signaling in cells expressing low levels of ErbB2. Altogether the results indicate that pertuzumab can be a valuable therapeutic agent not only in cancers overexpressing ErbB2 but also in cancers co-expressing ErbB2 and ErbB3.
Introduction
The ErbB family of receptor tyrosine kinases has four members: the epidermal growth factor (EGF) receptor (EGFR) (also known as ErbB1/HER1), ErbB2/HER2/Neu, ErbB3/HER3 and ErbB4/HER4. ErbB proteins vary with respect to their structural properties, their ligand binding capacity and their catalytic activity, but they are all involved in physiological and pathological processes, such as cell survival, proliferation and differentiation (reviewed in refs 1,2). Deregulated signaling is a feature of carcinogenesis. ErbB3 plays an important role in ErbB-driven cancers (3, 4) . ErbB3 has been shown to have marginal kinase activity, and downstream signaling reportedly happens as a result of ligand-induced heterodimerization (5, 6) . Both ErbB2 and ErbB3 are overexpressed in several human cancers, and ErbB2-ErbB3 heterodimers are potent signaling units in carcinogenesis (reviewed in refs 7,8) . The cytoplasmic tail of ErbB3 has six docking sites for direct binding of the p85 subunit of PI3 kinase (PI3K) (reviewed in ref. 9 ). Thus, signaling through ErbB3 is the major mechanism whereby the PI3K/Akt activity is initiated and enhanced downstream of the ErbB proteins. Such activity is of major importance with respect to development of treatment resistance (10) (11) (12) . Upon incubation with ErbB2 and/or EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and lapatinib, tumor cells eventually stop responding to the applied drugs by reactivating ErbB3. This happens by cross talk between signaling pathways, by upregulation of ErbB3 at the messenger RNA and protein levels and/or by relocating the receptor to the plasma membrane (12) (13) (14) (15) (16) (17) (18) .
Endocytosis and subsequent lysosomal degradation is one of the ways whereby signaling from ErbBs can be controlled (reviewed in ref. 19 ). Endocytosis of the EGFR is fairly well characterized, and it is known that the EGFR undergoes EGF-induced translocation to clathrin-coated pits, from where the EGF-EGFR complex is internalized and finally degraded in lysosomes (reviewed in ref. 20) . However, endocytosed EGFR can also be recycled to the plasma membrane, for example, upon tumor growth factor alpha-induced endocytosis. Such recycling will counteract downregulation of the EGFR (21) . ErbB2 is mostly localized to the plasma membrane but is generally excluded from clathrin-coated pits and has been considered to be relatively endocytosis resistant (22, 23) . ErbB2 is bound and stabilized by heat shock protein 90, and endocytosis and degradation of ErbB2 can be induced by the heat shock protein 90 inhibitor Geldanamycin and by Geldanamycin derivatives (23) (24) (25) (26) . ErbB3 was initially believed to be endocytosis resistant. However, we recently demonstrated that ErbB3 is in fact internalized constitutively in a clathrin-dependent manner and has a shorter half-life than non-activated EGFR (27) . Moreover, we observed that internalization of ErbB3 in the absence of added ligand happens regardless of the state of ErbB3 phosphorylation. A better understanding of molecular mechanisms involved in control of ErbB3 stability and trafficking should help tailoring therapeutic interventions, such as the use of pertuzumab (Perjeta TM ). ErbB2 is the preferred dimerization partner for other ErbB proteins (28) , and due to its endocytosis deficiency, ErbB2 also inhibits endocytosis of EGFR-ErbB2 heterodimers (29) . The monoclonal antibody pertuzumab specifically interacts with the dimerization arm of ErbB2 and inhibits ErbB2 dimerization (reviewed in ref. 30 ), and we previously demonstrated that pertuzumab thereby counteracted the ErbB2-imposed block in endocytosis of EGFR (31) . We also recently showed that pertuzumab, to a small and cell-type-dependent degree, may induce endocytosis of ErbB2 and increase endocytosis of ErbB2 in the presence of an heat shock protein 90 inhibitor (32) . Pertuzumab has also been demonstrated to disrupt signaling otherwise transmitted upon ligand-induced ErbB2 heterodimerization and thus to inhibit growth of cancer cells (33) (34) (35) (36) . In this study, we have investigated whether ErbB2 also counteracts internalization and degradation of ErbB3. We have made use of porcine aortic endothelial (PAE) cells stably expressing ErbB3 alone (PAE.ErbB3 cells) or in combination with EGFR (PAE.EGFR.ErbB3 cells) or ErbB2 (PAE.ErbB2.ErbB3 cells). In addition, we used the two breast cancer cell lines, MCF-7 and SK-BR-3, which have different levels of ErbB2 expression. Our results demonstrate that expression of ErbB2, as such, does not inhibit constitutive internalization of ErbB3 (in the absence of added ligand) but slows ligand-induced degradation of ErbB3 in cells overexpressing ErbB2. The latter was counteracted by pertuzumab, probably as a result of pertuzumab-mediated inhibition of ligand-induced ErbB2-ErbB3 dimerization. In line with this finding, pertuzumab also efficiently blocked ligand-induced signaling downstream of ErbB3 in MCF-7 cells expressing only small amounts of ErbB2.
Materials and methods

Materials
Heregulin β1 extracellular domain (HRG-β1 ECD) was from R&D Systems (Minneapolis, MN). Pertuzumab was provided by Roche Diagnostics GmbH (Mannheim, Germany). Other chemicals were from Sigma-Aldrich (St Louis, MO) unless otherwise noted.
Cell culture and treatment MCF-7 and SK-BR-3 cells were from the American Tissue Culture Collection (Manassas, VA) and were grown in Dulbecco's modified Eagle's medium with ultraglutamine 1 and 4.5 g/l glucose (Lonza Group Ltd, Basel, Switzerland). PAE cells, stably transfected to express ErbB3 (PAE.ErbB3 cells) or ErbB3 in combination with either EGFR (PAE.EGFR.ErbB3 cells) or ErbB2 (PAE.ErbB2. ErbB3 cells), were described previously (27, 29, 37) . These cells were grown in Ham's F-12 medium with l-glutamine (Lonza Group Ltd). A total of 400 µg/ml Geneticin (G418), 30 µg/ml Zeocin and 60 µg/ml Hygromycin B (all from Life Technologies Co., Carlsbad, CA) were added to the media as selection markers for stable expression of EGFR, ErbB2 and ErbB3, respectively. 0.5 × recommended concentration of penicillin-streptomycin (Lonza Group Ltd) and 10% fetal bovine serum were routinely used for all cells, except for SK-BR-3 cells, where 15% fetal bovine serum was used. For receptor activation experiments, 10 nM HRG-β1 (80 ng/ml) or 10 nM HRG-β1 ECD (269 ng/ml) was added to cells in minimal essential medium (MEM) without bicarbonate (Life Technologies Co.) in the presence of 0.1% bovine serum albumin (BSA). When investigating downregulation of ErbB3 from the plasma membrane, 25 µg/ml cycloheximide (CHX) was added to the cells. In experiments investigating degradation of ErbB3, cells were incubated with 25 µg/ml CHX either without ligand or with 10 nM HRG-β1 or 10 nM HRG-β1 ECD. In all experiments where pertuzumab was included, cells were preincubated with or without 25 µg/ml (100 µg/ml for SK-BR-3 cells) pertuzumab for 30 min on ice or 1 h at 37°C before incubation with ligand alone or with ligand and pertuzumab. 
Antibodies
Western blotting
Cells were lysed and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting as described previously (38) , and proteins were detected using SuperSignal West Dura Extended Duration Substrate from Pierce (Thermo Fisher Scientific). Proteins were visualized using the KODAK Image Station 4000R from Carestream Health (Rochester, NY) or the ChemiDoc MP System from Bio-Rad Laboratories (Hercules, CA). Densitometric quantitations were performed using KODAK Molecular Imaging software, version 4.0, or Image Lab Software, version 4.0.1 build 6 (Bio-Rad), and statistical significance was tested using the two-tailed Student's t-test. Images were processed using Adobe Photoshop.
Flow cytometry analysis
Cells were incubated as described in legend to Figure 3 before they were trypsinized and fixed in 10% neutral buffered formalin solution (~4% formaldehyde). Flow cytometry analysis was performed as described previously (39), using mouse anti-ErbB3 and phycoerythrin-conjugated goat anti-mouse IgG antibodies. The samples were analyzed using a FACS LSRII flow cytometer (BD Biosciences, San Jose, CA). A minimum of 20 000 cells were analyzed for each sample. Non-stained cells, incubated with the secondary antibody only, were included in the analysis to show background fluorescence. Statistical significance was tested using the two-tailed Student's t-test.
Immunocytochemistry and confocal microscopy
Cells were grown in 6 cm culture dishes and incubated as described in legend to Figure 3 before being fixed in 10% neutral buffered formalin solution (~4% formaldehyde) and immunostained as described (29) . The cells were then examined by confocal microscopy analysis (Olympus FluoView FV1000; Olympus Corporation, Tokyo, Japan, or Leica TCS SP; Leica Microsystems AG, Wetzlar, Germany), and images were processed using Adobe Photoshop.
Results
HRG induces phosphorylation of ErbB3 and activation of downstream signaling
Despite marginal kinase activity, we have previously demonstrated weak constitutive phosphorylation of ErbB3, as well as slightly increased ErbB3 phosphorylation upon addition of HRG in PAE cells expressing ErbB3 only. The observed increase in phosphorylation was inhibited by the kinase inhibitor AG1478 (27) . To study how expression of other ErbB proteins affect ErbB3 phosphorylation, we initially compared the level of EGFR, ErbB2 and ErbB3 in MCF-7 cells, in SK-BR-3 cells and in PAE cell lines expressing ErbB3 only, ErbB3 together with ErbB2 or ErbB3 together with EGFR. The EGFR was found to be efficiently expressed in PAE.EGFR.ErbB3 cells and to a lower extent in MCF-7 and SK-BR-3 cells (Figure 1 ). The weak band observed in PAE.ErbB2.ErbB3 cells upon blotting for EGFR most likely represents non-specific binding of anti-EGFR antibody to ErbB2. This was concluded based on the fact that ErbB2 has a higher molecular weight than EGFR and the observation that the band from PAE.ErbB2.ErbB3 cells is positioned slightly higher than the band representing EGFR in the other cell lines. ErbB2 was expressed at high levels in PAE.ErbB2.ErbB3 cells and in SK-BR-3 cells compared with MCF-7 cells (Figure 1 ). ErbB3 was expressed in all cell lines with the smallest amounts in MCF-7 cells and SK-BR-3 cells. The highest expression of ErbB3 was observed in PAE.ErbB2.ErbB3 cells and in PAE.ErbB3 cells (Figure 1 ). To visualize phosphorylation of ErbB3, as well as phosphorylation of downstream substrates, we performed western blotting using antibodies to phosphorylated ErbB3 (p-ErbB3), phosphorylated Akt (p-Akt) and phosphorylated Erk (p-Erk). To activate ErbB3, cells were incubated with HRG of which different isoforms exist. Both a short recombinant isoform of HRG (HRG-β1) and full-length HRG-β1 (here referred to as HRG-β1 ECD) have previously been shown to induce ErbB3 heterodimerization and initial phosphorylation of ErbB3 to the same extent. HRG-β1 ECD does, however, cause the most efficient ligand-induced degradation of ErbB3 (27, 40) . The reason for the latter difference is unclear, but it has been suggested that HRG-β1 ECD to a higher degree than HRG-β1 destabilizes higher order oligomers of ErbB3 (40) . Phosphorylation of ErbB3, Akt and Erk was observed in all cell lines upon incubation both with HRG-β1 and with HRG-β1 ECD (Figure 2A and B) . In line with our previous study (27) , a weak phosphorylation of ErbB3 was found in PAE.ErbB3 cells. Phosphorylation of ErbB3 and downstream effectors did, however, increase when the cells in addition to ErbB3 co-expressed either EGFR or ErbB2. Taking the expression level of ErbB3 in PAE. EGFR.ErbB3 cells and PAE.ErbB2.ErbB3 cells into consideration, the intensity of ErbB3 phosphorylation correlated with its expression level ( Figure 2A ). In line with increased expression of EGFR and ErbB2, HRG induced stronger phosphorylation of ErbB3 in SK-BR-3 cells compared with that in MCF-7 cells (Figure 2B
ErbB3 is downregulated from the plasma membrane and localizes to early endosomes in the absence of added ligand in cells co-expressing ErbB2
We have previously demonstrated that ErbB3 is internalized in the absence of added ligand in PAE.ErbB3 and PAE.ErbB3.EGFR cells (27) . We have also observed that overexpression of ErbB2 can inhibit EGF-induced internalization of the EGFR (29) . To investigate whether overexpression of ErbB2 has an inhibitory effect also on ErbB3 internalization, we initially compared the subcellular localization of ErbB2 and ErbB3 in PAE.ErbB2.ErbB3 cells by immunofluorescence labeling and confocal microscopy. As demonstrated in Figure 3A , ErbB2 was found to be mostly localized to the plasma membrane. ErbB3 was, however, found both at the plasma membrane and in intracellular vesicular compartments. To study whether the vesicular labeling for ErbB3 could represent endocytosed ErbB3, cells were incubated with an anti-ErbB3 antibody on ice followed by chase for 30 min at 37°C. We have previously shown that incubation with this antibody does not in itself induce endocytosis of ErbB3, and endocytosis of the antibody can thus be used to study constitutive internalization of ErbB3 (27) . We then localized the anti-ErbB3 antibody and stained the cells for total ErbB2 and early endosome antigen 1 (EEA1). As demonstrated in Figure 3B , the anti-ErbB3 antibody was found to be mostly localized in vesicles. The ErbB3-positive vesicles were partly positive also for EEA1, confirming their endosomal nature. To directly compare the rate of ErbB3 downregulation in PAE cells co-expressing EGFR or ErbB2, we used flow cytometry analysis to quantify ErbB3 at the plasma membrane after 5 h incubation either with or without CHX. Because CHX inhibits protein synthesis, incubation with CHX can be used to measure constitutive and ligand-induced downregulation of ErbB3 both by flow cytometry ( Figure 3C ) and by western blotting (see below). As demonstrated in Figure 3C , ErbB3 was downregulated in both cell lines to a similar extent regardless of the level of expression (for receptor expression levels, see Figure 1 ). Quantification of ErbB3 at the plasma membrane in three independent experiments showed that cell surface-localized ErbB3 was reduced by 49% in PAE. EGFR.ErbB3 cells and by 45% in PAE.ErbB2.ErbB3 cells in the absence of added ligand ( Figure 3D ). Although we cannot conclude that expression of ErbB2 has no inhibitory effect on internalization ErbB3 cells (A) and MCF-7 and SK-BR-3 cells (B) were incubated with or without 10 nM HRG-β1 or HRG-β1 ECD for 5 min at 37°C. The cells were then lysed and subjected to western blotting with antibodies to ErbB3 (rabbitanti-ErbB3), p-ErbB3, p-Akt and p-Erk. Western blotting with anti-transferrin receptor (TfR) antibody (A) or anti-α-adaptin antibody (B) was used as loading controls. Net luminescence values of bands corresponding to ErbB3 (representing total ErbB3), p-ErbB3, p-Akt and p-Erk were quantified. The p-ErbB3 and ErbB3 bands were first normalized to their respective loading controls, and the normalized values were used to calculate the p-ErbB3/ ErbB3 ratio. p-Akt and p-Erk were normalized to the respective loading controls, and all normalized values were plotted as ratios of control (no ligand) that was set to 1. Histograms are shown below the respective lanes. This figure demonstrates one representative experiment out of three.
of ErbB3 in the absence of added ligand, the results clearly show that expression of ErbB2 as such does not block constitutive ErbB3 internalization.
HRG-induced degradation of ErbB3 is reduced in cells expressing high levels of ErbB2
It has been demonstrated that ErbB3 is degraded in the absence of added ligand, but that its degradation is increased upon incubation with HRG-β1 ECD (27, 40) . We have previously demonstrated that overexpression of ErbB2 inhibits the EGF-induced degradation of EGFR (29), and we therefore investigated whether ErbB2 would similarly inhibit degradation of ErbB3 in the absence or presence of added ligand. This was examined by western blotting for ErbB3 in PAE. EGFR.ErbB3 and MCF-7 cells that either do not express or express only small amounts of ErbB2, and in PAE.ErbB2.ErbB3 and SK-BR-3 cells that express higher levels of ErbB2 ( Figure 4A ). Quantification Figure 4B ) demonstrated that already upon 4 h incubation with HRG-β1 ECD, the ErbB3 levels were significantly more reduced in cells expressing little or no ErbB2 compared with cells with high levels of ErbB2, indicating that heterodimerization with ErbB2 can inhibit degradation of ErbB3. Upon incubation for 8 h, the observed inhibitory effect of ErbB2 expression on ErbB3 downregulation was clearly significant upon incubation with both HRG-β1 and HRG-β1 ECD. When comparing PAE.EGFR. ErbB3 cells with PAE.ErbB2.ErbB3 cells at this time point, expression of ErbB2 appeared to also inhibit degradation of ErbB3 to some extent in the absence of added ligand. The effect did, however, turn out to be non-significant. Altogether, these data show that upon ligand binding to ErbB3, a condition that favors receptor dimerization, overexpression of ErbB2 significantly slows downregulation of ErbB3.
Pertuzumab reduces HRG-induced phosphorylation of ErbB3 in cells expressing ErbB2
Several reports have concluded that pertuzumab can inhibit the formation of ligand-induced ErbB2-ErbB3 heterodimers and for this reason also inhibit signaling that originates from these heterodimers (33) (34) (35) (36) 41) . We therefore characterized the effect of pertuzumab on HRG-induced signaling in cell lines expressing ErbB2 and ErbB3 compared with PAE.EGFR.ErbB3 cells. It has previously been reported that both HRG-β1 and HRG-β1 ECD initially activates ErbB3 to similar extent (40), and as described above, we did not detect significant differences in activation upon incubation with either ligand for 5 min at 37°C (see Figure 2) . To study the effect of pertuzumab on HRG-induced ErbB3 phosphorylation and downstream signaling, we initially performed incubations with pertuzumab followed by HRG on ice. Because internalization is then blocked, possible effects are restricted to ErbB2 and ErbB3 localized at the plasma membrane. As expected, pertuzumab had no effect in PAE.EGFR.ErbB3 cells. In cells expressing ErbB2, however, pertuzumab inhibited HRG-induced phosphorylation of ErbB3 ( Figure 5A ). Because no, or only minimal, phosphorylation of Akt and Erk was observed upon incubation with HRG on ice (data not shown), we repeated the experiment with the exception that all incubations were performed at 37°C ( Figure 5B) . In similarity to incubation on ice, pertuzumab inhibited HRGinduced phosphorylation of ErbB3 in cells expressing ErbB2, and in a cell-line-dependent manner, pertuzumab also affected downstream Fig. 4 . HRG-induced degradation of ErbB3 was reduced in cells expressing high levels of ErbB2. (A) PAE.EGFR.ErbB3, MCF-7, PAE.ErbB2.ErbB3 and SK-BR-3 cells were incubated without ligand (−), or with 10 nM HRG-β1 or HRG-β1 ECD for 4 and 8 h at 37°C. CHX (25 µg/ml) was included in all samples except the control condition (0 h). The cells were lysed and subjected to western blotting using rabbit anti-ErbB3 and anti-tubulin (loading control) antibodies. One representative western blot out of three is demonstrated. (B) Net luminescence values of bands corresponding to ErbB3 were quantified and normalized to the loading control. The average values of three independent experiments ± standard deviation were plotted as percentage of control (indicated by the stippled line). Statistical analysis was performed and significant differences (differences with P < 0.05) are indicated by asterisks (*).
signaling. Only in MCF-7 cells, which express low levels of EGFR and ErbB2, pertuzumab strongly reduced HRG-induced phosphorylation of Akt and Erk. No reduction in Akt and Erk phosphorylation was observed upon incubation with EGF (Supplementary Figure S1 , available at Carcinogenesis Online). Incubation with pertuzumab further had only marginal effect on phosphorylation of Akt and no effect on phosphorylation of Erk in PAE.ErbB2.ErbB3 cells ( Figure 5B ). The level of inhibition was not significantly increased upon increasing the concentration of pertuzumab from 25 to 100 μg/ml in PAE.ErbB2. ErbB3 cells (data not shown). For SK-BR-3 cells, we used 100 μg/ ml pertuzumab, because this more efficiently inhibited HRG-induced phosphorylation of ErbB3 compared with 25 μg/ml pertuzumab (data not shown). However, even this relatively high concentration of pertuzumab had only a marginal effect on phosphorylation of Akt and Erk in SK-BR-3 cells (Figure 5A and B) . In summary, pertuzumab reduced HRG-induced phosphorylation of ErbB3 in all three cell lines expressing ErbB2, but HRG-induced downstream signaling was efficiently reduced only in MCF-7 cells expressing small amounts of ErbB2. Our results further indicate that ErbB2-ErbB3 heterodimerization occurs at the plasma membrane, and that this dimerization can be counteracted by pertuzumab.
Pertuzumab enhances degradation of ErbB3 in cells expressing high levels of ErbB2
Because we have demonstrated previously that pertuzumab counteracts the inhibitory effect that ErbB2 has on EGF-induced degradation of the EGFR (31), we next investigated whether pertuzumab would also affect degradation of ErbB3. As demonstrated in Figure 6 , we found that pertuzumab did not seem to increase the constitutive or the ligand-induced degradation of ErbB3 in cells expressing no or only small amounts of ErbB2. However, in PAE.ErbB2.ErbB3 cells and in SK-BR-3 cells, expressing high levels of ErbB2, incubation with pertuzumab enhanced the degradation of ErbB3 upon incubation with HRG-β1 ECD for 8 h. Taken together, we conclude that pertuzumab counteracts the inhibitory effect of ErbB2 on ErbB3 internalization and degradation.
Discussion
Overexpression of the oncoprotein ErbB2 has been reported in several cancers. ErbB2 undergoes slow endocytosis, and it has been proposed that a major proportion of endocytosed ErbB2 is recycled to the plasma membrane (42) . This localization enables ErbB2 to readily interact with and activate the oncoproteins EGFR and ErbB3. We have previously shown that upon heterodimerization with ErbB2, endocytosis of the EGFR is strongly retarded (29, 31) . Furthermore, we have previously shown that ErbB3, when expressed along with the EGFR, is in contrast to the EGFR efficiently internalized and degraded without added ligand (27) . We now demonstrate that ErbB3 is degraded at a reduced rate in PAE.ErbB2.ErbB3 cells and in SK-BR-3 cells, both overexpressing ErbB2, compared with in PAE.ErbB3 or MCF-7 cells that express no or only limited amounts of ErbB2. The inhibitory effect of ErbB2 expression on ErbB3 degradation is most prominent upon stimulation with HRG-β1 and HRG-β1 ECD, conditions that efficiently allow ErbB2-ErbB3 heterodimerization. We therefore believe that ErbB3, especially upon ligand binding, heterodimerizes with ErbB2, and that overexpression of the inefficiently internalized ErbB2 prevents endocytosis and degradation of ErbB3. This is consistent with the contention that pertuzumab inhibits ErbB2 heterodimerization (30) and therefore allows efficient internalization and degradation of ErbB3. This is also consistent with our previous finding that pertuzumab, by blocking EGFR-ErbB2 dimerization, caused increased ligand-induced endocytosis and lysosomal degradation of the EGFR in cells overexpressing ErbB2 (31) .
Our current results strongly support the notion that pertuzumab inhibits the formation of ErbB2-containing heterodimers. However, the efficiency of this inhibition and its effect on oncogenic signaling have been debated (41, 43) . It is likely that the response to ErbB-directed immunotherapy is cell-type dependent (41, 44) . We now report that pertuzumab affects ErbB3 signaling in PAE cells expressing ErbB3 in combination with ErbB2 and in the breast cancer cell lines MCF-7 and SK-BR-3. Pertuzumab efficiently blocked HRG-induced phosphorylation of ErbB3 and downstream signaling in MCF-7 cells. However, pertuzumab did not affect MAPK and PI3K signaling in MCF-7 cells upon addition of EGF (Supplementary Figure S1 , available at Carcinogenesis Online). This suggests that while ErbB3, due to its limited kinase activity, depends on ErbB2-ErbB3 heterodimerization for efficient activation and signal transduction, signaling from EGFR homodimers is efficiently sustaining MAPK and PI3K signaling. The fact that pertuzumab effectively blocked HRG-mediated signaling without having detectable effect on ErbB3 degradation in MCF-7 cells supports the view that ErbB2-ErbB3 heterodimers are efficient signal transducers, but that due to the low expression of ErbB2, only a small amount of ErbB3 is engaged in ErbB2-ErbB3 heterodimers. These results further support the notion that ErbB3 can be internalized and degraded in the absence of tyrosine phosphorylation (27) . In PAE.ErbB2.ErbB3 cells, and to some extent in SK-BR-3 cells, we observed that pertuzumab reduced HRG-induced phosphorylation of ErbB3 without efficiently blocking activation of downstream signaling pathways, even at high concentrations of pertuzumab. In SK-BR-3 cells, the limited effect of pertuzumab on downstream signaling may be due to compensatory ligand-induced formation of EGFR-ErbB3 heterodimers. However, it could also indicate that activation of even small amounts of ErbB2-ErbB3 heterodimers is sufficient for efficient activation of downstream pathways. Alternatively, a small fraction of ErbB2 may have lost its extracellular domain by proteolytic shedding, resulting in the constitutively active form p95HER2 (45) . The truncated version of ErbB2 would not be inhibited by pertuzumab because it lacks its binding domain.
ErbB2-ErbB3-mediated signaling is important in development and progression of cancer and in cancer therapy resistance. Increased expression of ErbB3 at the plasma membrane and increased ErbB3 activity are known to be associated with poor prognosis in cancer. For ErbB2.ErbB3 and SK-BR-3 cells were preincubated with or without 25 µg/ml pertuzumab (100 µg/ml for SK-BR-3 cells) for 1 h at 37°C. Cells were then incubated with or without CHX (25 µg/ml)) either without ligand, or with 10 nM HRG-β1 ECD, with or without pertuzumab, for 8 h at 37°C. The cells were lysed and subjected to western blotting using rabbit anti-ErbB3 and anti-tubulin (loading control) antibodies. This figure demonstrates one representative experiment out of a minimum of three. (B) Net luminescence values of bands corresponding to ErbB3 were quantified, normalized to the loading control.
The average values of minimum three independent experiments ± standard deviation were plotted as percentage of control without CHX (indicated by the stippled line). Statistical analysis was performed and significant differences are indicated by asterisks (*). Single asterisk indicates P < 0.05, double asterisk indicates P < 0.01. such reasons, pertuzumab inhibiting ErbB2-ErbB3 dimerization should be clinically useful not only in cancer cells overexpressing ErbB2 but also in cancer cells expressing ErbB3 in the presence of ErbB2.
Supplementary material
Supplementary Figure 1 can be found at http://carcin.oxfordjournals. org/
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